Evidence method
Level · gp.fundamentals.debt_to_revenue
131.87% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ANIP · Mar 31, 2019
ANI PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001144204-19-024656General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
3.36% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
27.02% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
13.78% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
79.48% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
72.16% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
8.32% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
8.27% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
3.23% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History49 statesSelf-history eligible
Sep 30, 20218/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 35.00%
- Current
- 131.87%
- Delta
- 96.87%
- Previous
- 2.85%
- Current
- 3.36%
- Delta
- 0.51%
- Previous
- 33.27%
- Current
- 27.02%
- Delta
- -6.25%
- Previous
- 13.99%
- Current
- 13.78%
- Delta
- -0.21%
- Previous
- 20.09%
- Current
- 79.48%
- Delta
- 59.38%
- Previous
- 63.77%
- Current
- 72.16%
- Delta
- 8.38%
- Previous
- 17.54%
- Current
- 8.32%
- Delta
- -9.22%
- Previous
- 7.63%
- Current
- 8.27%
- Delta
- 0.63%
- Previous
- 3.36%
- Current
- 3.23%
- Delta
- -0.13%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ANIP Fundamental State →Has State · ANI PHARMACEUTICALS INC →Transitioned To · ANIP Fundamental State →Transitioned To · ANIP BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · ANIP CAPEX_INTENSITY_INCREASED →Transitioned To · ANIP CASH_GENERATION_DECREASED →Transitioned To · ANIP GROWTH_DECREASED →Transitioned To · ANIP MARGIN_INCREASED →Transitioned To · ANIP PROFITABILITY_DECREASED →Transitioned To · ANIP R_AND_D_INTENSITY_INCREASED →Transitioned To · ANIP SBC_INTENSITY_DECREASED →Transitioned To · ANIP INVENTORY_PRESSURE_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.